报价延迟最少15分钟:2026/04/26 19:09 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.88 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.27/-1.10
|
|
企业价值
343.42M
|
| 资产负债 |
|
每股账面净值
2.63
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
35.95M
|
|
每股收益
0.21
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products. |
